Adial Pharmaceuticals Warrant
ADILW
ADILW was delisted on the 27th of July, 2023.
1 hedge funds and large institutions have $1K invested in Adial Pharmaceuticals Warrant in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
50% less capital invested
Capital invested by funds: $2K → $1K (-$1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$88 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1K | -$88 | -428 | -5% |
|
ADILW Hedge Fund Activity: Q1 2020 in Review
1 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals Warrant (ADILW) for Q1 2020, worth a combined $1K — down 50% from $2K a quarter earlier.
Fund positioning in ADILW was balanced in Q1 2020: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $88.
- 1 institutional investor held Adial Pharmaceuticals Warrant (ADILW) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $1K of Adial Pharmaceuticals Warrant stock for Q1 2020, down 50% quarter-over-quarter.
- 0 funds opened new Adial Pharmaceuticals Warrant positions in Q1 2020 and 0 closed out.
- The largest Adial Pharmaceuticals Warrant seller in Q1 2020 was UBS Group, an estimated $88 sold.
Based on aggregated 13F filings for Q1 2020.